Institutional investors purchased a net $35.0 thousand shares of REGN during the quarter ended June 2016. This may signal that the smart money is gaining interest in this company as the 71.24% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
HARDING LOEVNER LP Bought 152.4 Thousand shares of Regeneron Pharmaceuticals